

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Kühn, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP03/03327

Title: Aqueous Formulations of (2-Hydroxymethyl-Indanyl-4-Oxy)-Phenyl-4,4,4-Trifluorobutane-1-Sulfonate

**MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
Susan M. Pellegrino  
Reg. No.: 48,972  
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-6450  
Facsimile: (203) 812-6459

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. [To Be Assigned]	Art Unit	Filing Date	App. No. / Pub. No. Le A 36 031
INFORMATION DISCLOSURE CITATION		Applicant(s) Kühn, et al.			

## U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F1	9	8	3	7	0	6	1	27/08/98	WO				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Mauler, et al., "Characterization of the Diarylether Sulfonylester (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a Potent Cannabinoid Receptor Agonist with Neuroprotective Properties," <i>J. Pharmacology and Experimental Therapeutics</i> , <u>302</u> (1), 359-368 (2002).
R2	Jarho, et al., "Hydroxypropyl-β-Cyclodextrin and its Combination with Hydroxypropyl-Methylcellulose Increases Aqueous Solubility of Δ <sup>9</sup> -Tetrahydrocannabinol," <i>Life Sciences</i> , <u>63</u> (26), 381-384 (1998).
R3	Loftsson, et al., "Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization," <i>J. Pharmaceutical Sciences</i> , <u>85</u> (10), 1017-1025 (1996).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.